UNLOCKING THE POTENTIAL OF THE IMMUNE SYSTEM WITH A NEW
CLASS OF THERAPEUTICS

Unlocking the potential
of the immune system
with a new class of
therapeutics

Proprietary glycan polymer with platform potential
stimulates antigen capture, uptake, and
immunological responses.
Intended to stimulate an immune response, thereby
enabling the rejection of cancer and other
diseases.

Practical Applications to Elevate Modern Medicine

Transforming
Interventional
Oncology

Injecting IP-001 following routine tumor ablations may transform this conventional surgical intervention into a systemically active immunotherapy.

Read More

Elevating
Immunotherapy

IP-001 upregulates T-cell activation, downregulates T-cell exhaustion, and drives stronger Th-1 and cytotoxic T-cell response, which could enhance other immunotherapies, such as checkpoint inhibitors.

Read More

Boosting
Vaccines

IP-001 is a powerful immunoadjuvant that enhances antigen-specific immunity against infectious diseases, including SARS-CoV-2, potentially increasing the efficacy of vaccines.

Read More

Immunophotonics is dedicated to developing its proprietary technology for the benefit of global human health. We believe our multimodal approach can elevate modern medicine, allowing everyday-routine treatments to provide enhanced outcomes.

The Latest News

April 13, 2022

Immunophotonics Announces Appointment of Miguel Zubizarreta to Its Board of Directors

Immunophotonics has strengthened its leadership with the appointment of Miguel Zubizarreta to its Board of Directors. Mr. Zubizarreta, a tech...
Read More
April 12, 2022

American Association for Cancer Research (AACR) Annual Meeting, April 8 – 13, 2022

Look for Tomas Hode, PhD, Co-Founder, CIO, and President at Immunophotonics, Inc. in New Orleans at the American Association for...
Read More
April 6, 2022

Immunophotonics Raises $21.4 Million in Equity Financing for Phase 2 Clinical Trials

Immunophotonics continues to attract investments that will fund research and clinical trials regarding the use of the company’s lead drug...
Read More